Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir | Zendy

Jennifer A. Fulcher | Zendy; Yushen Du | Zendy; Tianhao Zhang | Zendy; Ren Sun | Zendy; Raphael J. Landovitz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir

Author(s) -

Jennifer A. Fulcher,

Yushen Du,

Tianhao Zhang,

Ren Sun,

Raphael J. Landovitz

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy228

Subject(s) - dolutegravir , integrase , emtricitabine , virology , integrase inhibitor , human immunodeficiency virus (hiv) , drug resistance , medicine , antiretroviral therapy , tenofovir , genotype , pharmacology , biology , viral load , genetics , gene

Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research